β-Blocker Use for the Stages of Heart Failure
- 1 August 2009
- journal article
- review article
- Published by Elsevier BV in Mayo Clinic Proceedings
- Vol. 84 (8), 718-729
- https://doi.org/10.4065/84.8.718
Abstract
No abstract availableKeywords
This publication has 104 references indexed in Scilit:
- Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET)Heart, 2007
- Metoprolol Reverses Left Ventricular Remodeling in Patients With Asymptomatic Systolic DysfunctionCirculation, 2007
- A polymorphism within a conserved β 1 -adrenergic receptor motif alters cardiac function and β-blocker response in human heart failureProceedings of the National Academy of Sciences of the United States of America, 2006
- Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trialEuropean Heart Journal, 2005
- Benefits of inpatient initiation of β-blockersAmerican Heart Journal, 2004
- Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitusThe American Journal of Cardiology, 2004
- Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureHypertension, 2003
- The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart FailureNew England Journal of Medicine, 1996
- Antihypertensive therapy: Taking lipids into considerationAmerican Heart Journal, 1991
- Plasma Norepinephrine as a Guide to Prognosis in Patients with Chronic Congestive Heart FailureNew England Journal of Medicine, 1984